Nosis-Brain-001

Nosis-Brain-001 is an unnamed preclinical RNA medicine program being developed by Nosis Biosciences for the treatment of various neurological diseases. The program utilizes Nosis Bio's proprietary tissue-targeted delivery platform, which is designed to overcome the historical challenges of delivering RNA therapeutics to specific tissues, such as the brain, by identifying and utilizing novel receptor targets for cell-specific uptake. As of early 2025, the program is in the Functional In Vivo Delivery Validation stage of preclinical development. While the specific molecular targets and exact neurological indications have not yet been disclosed, the program represents the company's efforts to apply its high-throughput discovery technology to central nervous system disorders.

Other names

unnamed brain program